When Boehringer Ingelheim's COPD drug Stiolto Respimat won U.S. approval early last month, the company's head of pharma marketing and sales, Allan Hillgrove, acknowledged that payer arm-twisting happening stateside may make pricing tough. But now, the German drugmaker has nabbed some European approvals that should give the drug a lift.
Earlier this year, Boehringer Ingelheim said it was considering selling its U.S.-based generics business for up to €2 billion ($2.2 billion) to lighten its load and focus on drug development. Now, the company is moving one step closer to a sale as companies such as Hikma Pharmaceuticals, Mallinckrodt and Perrigo approach the bidding table.
Vitae Pharmaceuticals has slammed into another setback. The small biotech's lead drug, the diabetes therapy VTP-34072, failed the first leg of a mid-stage study executed by Boehringer Ingelheim.
Portola Pharmaceuticals has laid out the last batch of Phase III data on its "breakthrough" anti-anticoagulant andexanet alfa, filling in the numbers that will be reviewed by regulators considering the biotech's upcoming pitch for marketing approval. And right alongside that announcement comes the latest numbers from Boehringer Ingelheim's breakthrough program for idarucizumab, which is already under review as an antidote to its blockbuster Pradaxa.
Makers of respiratory drugs have been cutting prices as they vie for prime formulary positioning with payers. Boehringer's Spiriva has already taken a sales hit as a result, but now, the German pharma is hoping new combo med Stiolto can turn things around.
Boehringer Ingelheim's respiratory sales have taken a beating lately as competitors in the space vie for formulary positioning. And even with a new combo approval in the mix, that may not change.
Boehringer Ingelheim picked up FDA approval for a next-generation COPD treatment, looking to contend for a share of the fast-crowding market for combination therapies.
Boehringer Ingelheim has made a quick decision about Pharmaxis' non-alcoholic steatohepatitis (NASH) drug, striking a $250 million deal to buy the Phase I asset just two months after inking an option to acquire the program.
Boehringer Ingelheim has exercised an option to buy PXS4728A from Australia-based Pharmaxis and develop it for the treatment of the liver-related condition NASH with the candidate also showing potential in chronic obstructive pulmonary disease.
Slumping sales for cardiovascular drugs isn't exactly a new phenomenon for Big Pharma, with some of the industry's top drugmakers suffering from recent patent expirations. But a new report shows which CV franchises have been hurt the most.